Search

Your search keyword '"Carpten, John D"' showing total 667 results

Search Constraints

Start Over You searched for: Author "Carpten, John D" Remove constraint Author: "Carpten, John D"
667 results on '"Carpten, John D"'

Search Results

2. Advancing genomics to improve health equity

5. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

6. Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression

7. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.

8. Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer

9. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma

10. Association of ESR1 germline variants with TP53 somatic variants in breast tumors in a genome-wide study

11. Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients

15. Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry

16. Mentoring Minority Cancer Researchers of Tomorrow: Comparison of the Face-to-Face, Virtual, and Hybrid Training Methods of the CaRE2 Summer Cancer Research Education and Training Program.

17. Toward precision medicine in glioblastoma: the promise and the challenges

18. Association ofESR1germline variants withTP53somatic variants in breast tumors in a genome-wide study

20. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

22. Correction: Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients

23. Increased Incidence of DACH1 Mutation in Appalachian Women with Uterine Cancer and Altered Chemotherapy Sensitivity

24. Validation of Myc-Associated Protein X (MAX) regulation in growth hormone secreting and nonfunctional pituitary adenoma

26. Data from African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent

27. Supplementary Table from African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent

28. Supplementary Data from African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent

30. Supplementary Figure from African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent

31. Abstract 6074: Germline and somatic genomic profiling of urothelial carcinoma

32. Supplementary Figure 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

33. Supplementary Table 9 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

34. Supplementary Figure 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

35. Banner Authorship Members from Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network

36. Supplementary Table 4 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

37. Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

38. Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

39. Data from Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network

40. Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

41. Supplementary Table 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

42. Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

43. Supplementary Table 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

44. Supplementary Figure 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

45. Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

46. Supplementary Table 6 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

47. Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center: Structure, Innovations, and Initial Outcomes

48. Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search

49. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants

50. Table S1 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer

Catalog

Books, media, physical & digital resources